Volagidemab is under clinical development by Remd Biotherapeutics and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Volagidemab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Volagidemab (REMD-477, AMG-477) is under development for treatment of type 2 diabetes, type 1 diabetes, myocardial infarction, systolic heart failure and other indications. It is administered through subcutaneous route. The drug candidate is a fully human antibody that binds and blocks signaling via the human glucagon receptor (GCGR). It was also under development for the treatment of obesity.
Remd Biotherapeutics overview
Remd Biotherapeutics is a biopharmaceutical company. The company focus on discovering and developing bio-medicines to treat diabetes, cancer, and other diseases. Its pipeline products include REMD 477 and others. REMD Biotherapeutics offers REMD 477 for the treatment of type 1 and type 2 diabetes, and for cardiovascular and other indications. The company also develops products for immune-oncology, and cardiovascular and metabolism; and provides research and development services. REMD Biotherapeutics is headquartered in Camarillo, California, the US.
For a complete picture of Volagidemab’s drug-specific PTSR and LoA scores, buy the report here.